Abstract
Survanta is commonly used as replacement therapy in newborn infants suffering from surfactant deficiency. We investigated the effects of Survanta and surfactant-like liposomes in the presence and absence of surfactant protein A (SP-A) on host defense functions of rat alveolar macrophages (AM). Phagocytosis of Streptococcus pneumoniae by AM was significantly inhibited in the presence of 100 μg/mL of Survanta. The ability of SP-A to enhance phagocytosis of S. pneumoniae was significantly compromised upon exposure to either Survanta or liposomes, although the overall level of phagocytosis remained higher than in the absence of SP-A. This inhibitory effect was not overcome by opsonization of the bacteria with SP-A before incubation with Survanta and AM. We also found that the ability of SP-A to mediate the association of group B Streptococcus with AM was compromised to a significant degree when exposed to either Survanta or liposomes in concentrations of 150 and 250 μg/mL. However, at most concentrations of Survanta or liposomes tested, the presence of SP-A resulted in significantly higher levels of bacterial association. These data show that Survanta and surfactant-like lipids suppress host defense functions of AM in the presence and absence of SP-A in vitro, although SP-A continues to enhance host defense functions overall.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- SP-A:
-
surfactant protein A
- FACS:
-
fluorescent activated cell sorter
- GBS:
-
group B Streptococcus
- AM:
-
alveolar macrophage(s)
- RDS:
-
respiratory distress syndrome
- DPBS:
-
Dulbecco's PBS
References
Avery M, Mead J 1959 Surface properties in relation to atelectasis and hyaline membrane disease. Am Med Assoc J Dis Child 97: 517–523
Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T 1980 Artificial surfactant therapy in hyaline-membrane disease. Lancet 1: 55–59
Auten RL, Watkins RH, Shapiro DL, Horowitz S 1990 Surfactant apoprotein A (SP-A) is synthesized in airway cells. Am J Respir Cell Mol Biol 3: 491–496
Korfhagen TR, Bruno MD, Ross GF, Huelsman KM, Ikegami M, Jobe AH, Wert SE, Stripp BR, Morris RE, Glasser SW, Bachurski CJ, Iwamoto HS, Whitsett JA 1996 Altered surfactant function and structure in SP-A gene targeted mice. Proc Natl Acad Sci USA 93: 9594–9599
LeVine AM, Kurak KE, Wright JR, Watford WT, Bruno MD, Ross GF, Whitsett JA, Korfhagen TR 1999 Surfactant protein-A binds group B streptococcus enhancing phagocytosis and clearance from lungs of surfactant protein-A-deficient mice. Am J Respir Cell Mol Biol 20: 279–286
Manz-Keinke H, Plattner H, Schlepper-Schafer J 1992 Lung surfactant protein A (SP-A) enhances serum-independent phagocytosis of bacteria by alveolar macrophages. Eur J Cell Biol 57: 95–100
Pikaar JC, Voorhout WF, van Golde LMG, Verhoef J, van Strijp JAG, van Iwaarden JF 1995 Opsonic activities of surfactant proteins A and D in phagocytosis of gram-negative bacteria by alveolar macrophages. J Infect Dis 172: 481–489
Tino MJ, Wright JR 1996 Surfactant protein A stimulates phagocytosis of specific pulmonary pathogens by alveolar macrophages. Am J Physiol 14: L677–L688
van Iwaarden F, Welmers B, Verhoef J, Haagsman HP, van Golde LM 1990 Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 2: 91–98
Wright JR, Youmans DC 1993 Pulmonary surfactant protein-A stimulates chemotaxis of alveolar macrophage. Am J Physiol 264: L338–L344
Schagat TL, Tino MJ, Wright JR 1999 Regulation of protein phosphorylation and pathogen phagocytosis by surfactant protein A. Infect Immun 67: 4693–4699
Mariencheck WI, Savov J, Dong Q, Tino MJ, Wright JR 1999 Surfactant protein A enhances alveolar macrophage phagocytosis of a live, mucoid strain ofP. aeruginosa. Am J Physiol 277: L777–L786
LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA, Korfhagen TR 1997 Surfactant protein-A deficient mice are susceptible to group B streptococcal infection. J Immunol 158: 4336–4340
Borron P, McIntosh JC, Korfhagen TR, Whitsett JA, Taylor J, Wright JR 2000 Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. Am J Physiol 278: L840–L847
Green GM, Kass EH 1964 The role of the alveolar macrophage in the clearance of bacteria from the lung. J Exp Med 119: 167–176
Alenghat E, Esterly JR 1984 Alveolar macrophages in perinatal infants. Pediatrics 74: 221–223
Zeligs BJ, Nerurkar LS, Bellanti JA, Zeligs JD 1977 Maturation of the rabbit alveolar macrophage during animal development. I. Perinatal influx into alveoli and ultrastructural differentiation. Pediatr Res 11: 197–208
Evans MJ, Sherman MP, Campbell LA, Shami SG 1987 Proliferation of pulmonary alveolar macrophages during postnatal development of rabbit lungs. Am Rev Respir Dis 136: 384–387
Sherman MP, Evans MJ, Campbell LA 1988 Prevention of pulmonary alveolar macrophage proliferation in newborn rabbits by hyperoxia. J Pediatr 112: 782–786
Hall SL, Sherman MP 1992 Intrapulmonary bacterial clearance of type III group B streptococcus is reduced in preterm compared with term rabbits and occurs independent of antibody. Am Rev Respir Dis 145: 1172–1177
Nerurkar LS, Zeligs BJ, Bellanti JA 1977 Maturation of the rabbit alveolar macrophage during animal development. II. Biochemical and enzymatic studies. Pediatr Res 11: 1202–1207
Sherman MP, D'Ambola JB, Aeberhard EE, Barrett CT 1988 Surfactant therapy of newborn rabbits impairs lung macrophage bactericidal activity. J Appl Physiol 65: 137–145
Zeligs BJ, Nerurkar LS, Bellanti JA 1984 Chemotactic and candidacidal responses of rabbit alveolar macrophages during postnatal development and the modulating roles of surfactant in these responses. Infect Immun 44: 379–385
Hayakawa H, Myrvik QN, St Clair RW 1989 Pulmonary surfactant inhibits priming of rabbit alveolar macrophage. Evidence that surfactant suppresses the oxidative burst of alveolar macrophages in infant rabbits. Am Rev Respir Dis 140: 1390–1397
Sherman MP, Goetzman BW, Ahlfors CE, Wennberg RP 1980 Tracheal aspiration and its clinical correlates in the diagnosis of congenital pneumonia. Pediatrics 65: 258–263
Ablow RC, Driscoll SG, Effmann EL, Gross I, Jolles CJ, Uauy R, Warshaw JB 1976 A comparison of early-onset group B streptococcal neonatal infection and the respiratory-distress syndrome of the newborn. N Engl J Med 294: 65–70
Herting E, Gefeller O, Land M, van Sonderen L, Harms K, Robertson B 2000 Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics 106: 957–964
Wright JR, Wager RE, Hawgood S, Dobbs L, Clements JA 1987 Surfactant apoprotein Mr=26,000–36,000 enhances uptake of liposomes by type II cells. J Biol Chem 262: 2888–2894
Tino MJ, Wright JR 1999 Surfactant proteins A and D specifically stimulate directed actin-based responses in alveolar macrophages. Am J Physiol 276: L164–L174
Dong Q, Wright JR 1998 Degradation of surfactant protein D by alveolar macrophages. Am J Physiol 18: L97–L105
Chida S, Phelps DS, Cordle C, Soll R, Floros J, Taeusch HW 1988 Surfactant-associated proteins in tracheal aspirates of infants with respiratory distress syndrome after surfactant therapy. Am Rev Respir Dis 137: 943–947
Gerdes J, Whitsett J, Long W 1992 Elastase activity and surfactant protein concentration in tracheal aspirates from neonates receiving synthetic surfactant. J Pediatr 120: S34–S39
Hallman M, Merritt TA, Akino T, Bry K 1991 Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. Am Rev Respir Dis 144: 1376–1384
Moya FR, Montes HF, Thomas VL, Mouzinho AM, Smith JF, Rosenfeld CR 1994 Surfactant protein A and saturated phosphatidylcholine in respiratory distress syndrome. Am J Respir Crit Care Med 150: 1672–1677
Wright JR, Dobbs LG 1991 Regulation of pulmonary surfactant secretion and clearance. In: Hoffman JF (ed) Annual Review of Physiology. Annual Reviews, Palo Alto, pp 395–414.
Wright JR 1997 Immunomodulatory functions of surfactant. Physiol Rev 77: 931–962
Kremlev SG, Phelps DS 1997 Effect of SP-A and surfactant lipids on expression of cell surface markers in the THP-1 monocytic cell line. Am J Physiol 272: L1070–L1077
Kremlev SG, Phelps DS 1994 Surfactant protein A stimulation of inflammatory cytokine and immunoglobulin production. Am J Physiol 267: L712–L719
Kremlev SG, Umstead TM, Phelps DS 1994 Effects of surfactant protein A and surfactant lipids on lymphocyte proliferation in vitro. Am J Physiol 267: L357–L364
Stamme C, Wright JR 1999 Surfactant protein A enhances the binding and deacylation ofE. coliLPS by alveolar macrophages. Am J Physiol 276: L540–L547
Acknowledgements
The authors thank Mike Cook and Lynn Martinek of the Duke Cancer Center for their assistance with FACS analysis.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by National Institutes of Health, National Research Service Award HL07538 and RO1 HL-51134 from the National Heart, Lung and Blood Institute.
An abstract pertaining to this work was presented in a poster session at the Society for Pediatric Research Meeting, Baltimore, MD, U.S.A., April-May 2001.
Rights and permissions
About this article
Cite this article
Golioto, A., Wright, J. Effects of Surfactant Lipids and Surfactant Protein A on Host Defense Functions of Rat Alveolar Macrophages. Pediatr Res 51, 220–227 (2002). https://doi.org/10.1203/00006450-200202000-00016
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-200202000-00016
